Gilead Sciences said total revenues for the 3 months ended September 30, 2025 increased 3% to $7.8 billion. HIV product sales increased 4% to $5.3 billion, and Liver Disease product sales increased 12% to $819 million.

1. 01

   Gilead Sciences said total revenues for the 3 months ended September 30, 2025 increased 3% to $7.8 billion. HIV product sales increased 4% to $5.3 billion, and Liver Disease product sales increased 12% to $819 million.

2. 02

   The company said net income attributable to Gilead for the 3 months was $3.1 billion and diluted earnings per share attributable to Gilead was $2.43. It cited as factors for the increase compared to net income attributable to Gilead of $1.3 billion and diluted earnings per share attributable to Gilead of $1.00 in the prior-year period the fact that a $1.8 billion in-process research and development partial impairment charge in Q3 2024 did not repeat in the current period.

3. 03

   Gilead Sciences said it used $3.0 billion for dividend payments, $1.8 billion for debt repayment and $1.7 billion for common share repurchases during the 9 months ended September 30, 2025. Share repurchase spending in the prior-year period was $800 million.

4. 04

   The company said settlement agreements in Biktarvy patent litigation with 3 generic manufacturers set the earliest date for generic sales in the U.S. at April 1, 2036, subject to standard acceleration provisions. It also announced the acquisition of Interius BioTherapeutics for approximately $350 million.

Key figures

Quarter ended September 30, 2025

Revenue

$7.8B

Operating income

$3.3B

Net income

$3.1B

EPS

$2.43

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.